Abstract
The close association between bladder cancer and modulation of the immune system has been known for many years. Reactivity to surface antigens, such as the ABO blood group antigens and the T group antigens, is often lost with the development of bladder cancer. These findings, together with the accessibility of the bladder mucosa to direct, topical treatment, have permitted and justified an immunotherapeutic approach to bladder cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Torti FM et al. (1984) Superficial bladder cancer is responsive to Alpha-2b-Interferon administered intravesically. Proc ASCO:C-628
Borden EC et al. (1984) L Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 132:800
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hasun, R., Höltl, W., Albrecht, W., Marberger, M. (1990). How Effective is Topical Interferon-α 2b for Preventing Recurrence of Superficial Bladder Cancer. In: Jakesz, R., Rainer, H. (eds) Progress in Regional Cancer Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74818-9_38
Download citation
DOI: https://doi.org/10.1007/978-3-642-74818-9_38
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74820-2
Online ISBN: 978-3-642-74818-9
eBook Packages: Springer Book Archive